Alzamend Neuro Receives FDA “Study May Proceed” Notice in PTSD

 

• Alzamend’s recently completed Phase IIA study of AL001 in Alzheimer’s patients and healthy subjects showed a benign safety profile and identified a candidate dose that is unlikely to require therapeutic drug monitoring
• Safety aspects of AL001 development may qualify for a 505(b)(2) NDA pathway for FDA approval

https://www.businesswire.com/news/home/20231211519845/en/PTSD